Evaluation the relationship of LUTS and urine pH, and efficacy of the citrates in patients with LUTS.

Evaluation the relationship of LUTS and urine pH, and efficacy of the citrates in patients with LUTS. - Safety and efficacy of the citrates in patients with LUTS.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001761

Enrollment

150

Registered

2009-03-09

Start date

2009-03-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

LUTS

Interventions

The citrates 1 gram X 3 per day orally, four weeks. (if dose increased, four more weeks.)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Patients with LUTS ,age >=20 years. 2) Signed and dated informed consent document indicating that patient has been informed of all pertinent aspects of this trial prior to enrollment. 3) Patients who are observed acidic urine and pain of LUT in their voiding diary, will be enrolled into the treatment phase.

Exclusion criteria

Exclusion criteria: 1) Urinary tract infection. 2) Urinary calculus or bladder calculus. 3) Prostate cancer. 4) Bladder tumor. 5) Grossly bloody urine of unknown cause. 6) Serious liver disease or kidney disease. 7) Women who are known or suspected to be pregnant, breastfeeding or desire to become pregnant during the trial period. 8) Patients who are judged unfit to enroll in this trial by the investigator.

Design outcomes

Primary

Measure	Time frame
Urinary frequency, pain, QOL (King's health questionnaire, ICSI, ICPI)	—

Secondary

Measure	Time frame
Quality of sleep (Pittsburg sleep quality index, Epworth sleepiness scale)	—

Countries

Japan

Contacts

Public ContactTomohiro Ueda

Kyoto City Hospital Department of Urology

tom-nobu@muf.biglobe.ne.jp075-311-5311

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026